NEW YORK (GenomeWeb News) — Illumina has licensed Oxford Gene Technology patents that will enable Illumina to detect DNA sequence variations, OGT said today.
 
Under the deal, OGT has granted Illumina access to the property through the life of the patents and provides “certain rights with respect to SNP genotyping,” OGT said.
 
Illumina CEO Jay Flatley said the licensing agreement is “relevant to a portion of our products and will not materially impact our expected financial results."
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.